These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34058344)

  • 1. Discovery and optimization of selective RET inhibitors via scaffold hopping.
    Luo Z; Wang L; Fu Z; Shuai B; Luo M; Hu G; Chen J; Sun J; Wang J; Li J; Chen S; Zhang Y
    Bioorg Med Chem Lett; 2021 Sep; 47():128149. PubMed ID: 34058344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
    Li X; Su J; Yang Y; Lian W; Deng Z; Yang Z; Chen G; Zhang B; Dong C; Liu X; Li L; Wang Z; Hu Z; Xu Q; Deng X
    Eur J Med Chem; 2020 Dec; 207():112755. PubMed ID: 32882611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
    Yoon H; Shin I; Nam Y; Kim ND; Lee KB; Sim T
    Eur J Med Chem; 2017 Jan; 125():1145-1155. PubMed ID: 27814560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma.
    Wang M; Naganna N; Sintim HO
    Bioorg Chem; 2019 Sep; 90():103052. PubMed ID: 31226468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
    La Pietra V; Sartini S; Botta L; Antonelli A; Ferrari SM; Fallahi P; Moriconi A; Coviello V; Quattrini L; Ke YY; Hsing-Pang H; Da Settimo F; Novellino E; La Motta C; Marinelli L
    Eur J Med Chem; 2018 Apr; 150():491-505. PubMed ID: 29549836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach.
    Saha D; Ryan KR; Lakkaniga NR; Smith EL; Frett B
    ChemMedChem; 2021 May; 16(10):1605-1608. PubMed ID: 33559353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective RET kinase inhibition for patients with RET-altered cancers.
    Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
    Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.
    Zhang L; Moccia M; Briggs DC; Bharate JB; Lakkaniga NR; Knowles P; Yan W; Tran P; Kharbanda A; Wang X; Leung YK; Frett B; Santoro M; McDonald NQ; Carlomagno F; Li HY
    J Med Chem; 2022 Jan; 65(2):1536-1551. PubMed ID: 35081714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor.
    Sun QZ; Xu Y; Liu JJ; Zhang CH; Wang ZR; Zheng RL; Wang WJ; Li LL; Yang SY
    Mol Divers; 2014 May; 18(2):403-9. PubMed ID: 24515340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Human-Derived
    Schubert L; Le AT; Estrada-Bernal A; Doak AE; Yoo M; Ferrara SE; Goodspeed A; Kinose F; Rix U; Tan AC; Doebele RC
    Mol Pharmacol; 2021 Jun; 99(6):435-447. PubMed ID: 33795352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
    Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
    Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
    De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
    J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of
    Mologni L; Dalla Via M; Chilin A; Palumbo M; Marzaro G
    ChemMedChem; 2017 Aug; 12(16):1390-1398. PubMed ID: 28639308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions.
    Zhang Y; Chan S; He R; Liu Y; Song X; Tu ZC; Ren X; Zhou Y; Zhang Z; Wang Z; Zhou F; Ding K
    Eur J Med Chem; 2022 Dec; 244():114862. PubMed ID: 36308779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.
    Yoon H; Kwak Y; Choi S; Cho H; Kim ND; Sim T
    J Med Chem; 2016 Jan; 59(1):358-73. PubMed ID: 26652860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.
    Frett B; Moccia M; Carlomagno F; Santoro M; Li HY
    Eur J Med Chem; 2014 Oct; 86():714-23. PubMed ID: 25232968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
    Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
    Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.